Cystic Fibrosis and associated Complications

被引:4
|
作者
Schwarz, C. [1 ]
Staab, D. [1 ]
机构
[1] Charite, Campus Virchow Klinikum, Christiane Herzog Zentrum, Klin Padiatrie MS Pneumol & Immunol,Sekt Cyst Fib, D-13353 Berlin, Germany
来源
INTERNIST | 2015年 / 56卷 / 03期
关键词
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; TRANSMEMBRANE CONDUCTANCE REGULATOR; FLUID; ANTIBIOTICS; MAINTENANCE; MORTALITY; CHILDREN; EFFICACY; MUTATION; THERAPY;
D O I
10.1007/s00108-014-3646-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cystic fibrosis (CF) is an autosomal recessive inherited metabolic disease. The mutation is located on the long arm of chromosome 7. Due to a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, chloride ion transport is reduced across the cell membrane. As a result, the disease can be described as an exocrinopathy. In all organs with exocrine glands, disorders occur in association with the defective chloride transport. The main impact of this defect is manifested in the lungs. Therefore, the most common cause of death is pulmonary disease with respiratory insufficiency due to recurrent infections. Unfortunately, a cure for the disease is still not available. However, new therapies that may affect the CFTR mutation more specifically give new hope for better therapeutic options in the future. The long-term goal of therapy is to develop a causal therapy for all six different mutation classes and thus for about 2000 mutations.
引用
收藏
页码:263 / 273
页数:11
相关论文
共 50 条
  • [1] Endocrine Complications of Cystic Fibrosis
    Kelly, Andrea
    Marks, Brynn E.
    Stalvey, Michael S.
    CLINICS IN CHEST MEDICINE, 2022, 43 (04) : 773 - 789
  • [2] Pulmonary Complications of Cystic Fibrosis
    Flume, Patrick A.
    RESPIRATORY CARE, 2009, 54 (05) : 618 - 625
  • [3] Gastrointestinal Complications of Cystic Fibrosis
    Gelfond, Daniel
    Borowitz, Drucy
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) : 333 - 342
  • [4] Prevention of drug-related complications in cystic fibrosis
    van der Meer, Renske
    Touw, Daan J.
    Heijerman, Harry G. M.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (06) : 666 - 673
  • [5] Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients
    Waters, Valerie J.
    Stanojevic, Sanja
    Sonneveld, Nicole
    Klingel, Michelle
    Grasemann, Haitmut
    Yau, Yvonne C. W.
    Tullis, Elizabeth
    Wilcox, Pearce
    Freitag, Andreas
    Chilvers, Mark
    Ratjen, Felix A.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (06) : 755 - 762
  • [6] Cardiovascular complications in cystic fibrosis: A review of the literature
    Poore, T. Spencer
    Taylor-Cousar, Jennifer L.
    Zemanick, Edith T.
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (01) : 18 - 25
  • [7] The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis
    Hong, Gina
    Alby, Kevin
    Ng, Sharon C. W.
    Fleck, Victoria
    Kubrak, Christina
    Rubenstein, Ronald C.
    Dorgan, Daniel J.
    Kawut, Steven M.
    Hadjiliadis, Denis
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (01) : 125 - 130
  • [8] Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the US Cystic Fibrosis Foundation Patient Registry
    Sears, Edmund H., Jr.
    Hinton, Alexandra C.
    Lopez-Pintado, Sara
    Lary, Christine W.
    Zuckerman, Jonathan B.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2023, 20 (09) : 1250 - 1257
  • [9] Aspergillus infections in cystic fibrosis
    King, Jill
    Brunel, Shan F.
    Warris, Adilia
    JOURNAL OF INFECTION, 2016, 72 : S50 - S55
  • [10] Precision medicine in cystic fibrosis
    Andrade, Arlette
    Ester Pizarro, Maria
    REVISTA MEDICA CLINICA LAS CONDES, 2022, 33 (01): : 44 - 50